Board of Directors

Charlie Cohen, PhD - Chairman/Chief Executive Officer

Charles Cohen, PhD has spent the past 28 years working as an entrepreneur, senior executive and investor in the biopharmaceutical industry and has focused on healthcare and life science venture capital since 2003. Charles is a co-founder of Synthesis Capital, where he focuses on investments in private companies in the biopharmaceutical and medical technology industries. From 2003 to 2007, Dr. Cohen was a Partner at the global private equity firm Advent International as a member of the healthcare and life science venture deal team. His responsibilities include sourcing, evaluating and managing portfolio company investments across the HCLS II and HCLS III funds. Prior to joining Advent, Dr. Cohen was a successful serial entrepreneur, having co-founded or served as senior executive/Board member of eleven companies, seven of which were Advent portfolio companies including Cellzome (acquired by GlaxoSmithKline) and leading public companies such as Exelixis (Nasdaq:EXEL) and Anadys Pharmaceuticals (Nasdaq:ANDS, acquired by Roche). Prior to this, in 1982 Dr. Cohen co-founded Creative BioMolecules (Nasdaq:CBMI, which merged with two other biotechnology companies in 2000 and now trades as Nasdaq:CRIS) and was a director and its Chief Executive Officer from 1985 to 1995. In addition Dr. Cohen served as special advisor to Paine Webber where he served as a director of several clinical R&D partnerships, including those affiliated with Genzyme (Nasdaq:GENZ, acquired by Sanofi), Cephalon (Nasdaq:CEPH, acquired by Teva), Alkermes (Nasdaq:ALKS) and ICOS (Nasdaq:ICOS, acquired by Eli Lilly). Charles currently serves as a member of the Advisory Council to the Harvard University Technology Development Accelerator Fund and a director of Foundation Sante.

Dr. Cohen is currently an active Board Member of the following portfolio companies: Ampla Pharmaceuticals, Exelixis (Nasdaq:EXEL), Prexa Pharmaceuticals and Sirion Therapeutics (sold to Alcon and Bausch & Lomb).

Charles received a BA from the University of New York at Buffalo, a PhD from New York University School of Medicine and completed a post doctoral fellowship at the University of Virginia.

David J. Chapman, PhD

Senior Director, CNS Project Champion, Teva Pharmaceuticals

David has 25 years of experience in the pharmaceutical industry. He joined the R&D Project Leadership team at Teva in March 2015 with responsibility for leading Neuroscience projects. Before Teva, David spent 14 years with Shire and was most recently in Shires Business Development group with responsibility for the identification and evaluation of new opportunities for in-licensing or acquisition in Neuroscience and GI.

David previously worked in project leadership roles in the US, UK & Europe with Shire, Ipsen, Janssen and Quintiles with an emphasis on CNS programs and started his career in the industry with SmithKline Beecham in their Pharmacokinetics department.

David completed his education in the UK and received a BSc degree in Physiology & Biochemistry from the University of Southampton and a PhD in Pharmacology & Pharmacokinetics from the University of Surrey.

Jason S. Fisherman, MD

Jason Fisherman, MD began his career in venture capital in 1994 and has focused on healthcare and life science investing for the past 20 years. Dr. Fisherman is a co-founder of Synthesis Capital, where he focuses on biopharmaceuticals and medical information technologies. From 1994 to 2007, he was at the global private equity firm Advent International and a Managing Director from 2002. There he led investments in over 20 companies, including Exelixis (Nasdaq:EXEL), ILEX Oncology (Nasdaq:ILXO acquired by Genzyme), Cubist Pharmaceuticals (Nasdaq:CBST), Crucell (Nasdaq/Euronext:CRXL, acquired by Johnson and Johnson), deCode (Nasdaq:DCGN), Anadys Pharmaceuticals (Nasdaq:ANDS, acquired by Roche), Gamera Biosciences (acquired by Tecan Group), Managed Healthcare Associates (MHA), Physicians Online (acquired by WebMD Health), Oridion Systems (SW:ORIDN, acquired by Covidien), Cellzome (acquired by GlaxoSmithKline) and Aegerion (Nasdaq:AEGR). Prior to joining Advent International, Dr. Fisherman had over ten years of drug research and clinical development experience in biotechnology, academia and the National Cancer Institute. A medical oncologist by training, he currently serves on the Visit Committee at the Dana Farber Cancer Institute.

Dr. Fisherman currently serves on the boards of the following portfolio companies: Achillion Pharmaceuticals (Nasdaq:ACHN), Ampla Pharmaceuticals, Nereus Pharmaceuticals, Prexa Pharmaceuticals and Spear Therapeutics.

Dr. Fisherman received a BA in Molecular Biophysics and Biochemistry from Yale, an MD from the University of Pennsylvania and an MBA from the Wharton School of the University of Pennsylvania. He is board certified in internal medicine and medical oncology.

Tom Needham, MBA

Tom Needham, MBA has spent the last 20 years working in healthcare and the biopharmaceutical industry and has focused on life science venture capital investing since 2002. Mr. Needham is a co-founder of Synthesis Capital, where he focuses on investments in private companies in the biopharmaceutical and medical technology industries. From 2002 to 2007, he was a Principal at the global private equity firm Advent International as a member of the healthcare and life sciences venture deal team. His responsibilities include sourcing, evaluating and managing portfolio company investments across the HCLS II and HCLS III funds. Over this time he has had Board and investment experience working on Astex Pharmaceuticals (Nasdaq:ASTX, acquired by Otsuka), Enanta Pharmaceuticals (Nasdaq:ENTA), MDEverywhere (acquired by Marlin Equity Partners) and Sirion Therapeutics (sale to Alcon and Bausch & Lomb). Prior to joining Advent, Mr. Needham was Vice President, Business Development at GPC Biotech, AG (FSE:GPC/Nasdaq:GPCB) with senior management responsibilities for U.S. corporate and business development, in-licensing and out licensing. Prior to this, he served as Vice President of Business Development at Mitotix, Inc, an oncology drug discovery company that included Advent International as one of its venture investors. As a member of the senior management team, Tom worked to merge Mitotix with GPC Biotech and played an active role in the combined company’s IPO in 2000. During his Mitotix/GPC tenure, Tom served as co-chair and treasurer of the Massachusetts Biotechnology Council Business Development Committee and served on the BIO Business Development Committee. Prior to joining Mitotix in 1994, Tom worked in business development at ImmuLogic Pharmaceutical Corp (Nasdaq:IMUL).

Mr. Needham is currently a Director on the Boards of Trident Pharmaceuticals (also acting CEO), Prexa Pharmaceuticals, Spear Therapeutics (also acting CEO) and is an active Board Observer at Ampla Pharmaceuticals.

Tom received a BA cum laude, from Bowdoin College and an MBA, with high distinction, from Babson Colleges Olin School of Management.

back to top